Introduction Taurolock® (Bio-Implant HealthCare, Winsen, Germany) is an anti-microbial agent (taurolidine) with anticoagulant properties (citrate). There is evidence that Taurolock® is beneficial in reducing catheter-related blood stream infections (CRBSI) in haemodialysis patients, but there are fewer data regarding benefit in home parenteral nutrition (HPN) patients.1 ,2 At St Mark's Intestinal Failure Unit Taurolock® is prescribed for patients with greater than three CRBSI in a 12-month period. The primary aim was to determine the incidence of CRBSI prior and subsequent to Taurolock® use. The secondary aim was to establish cost benefit from Taurolock® prescription.
Methods Retrospective audit using St Mark's Intestinal Failure (IF) Database. ::::CRBSI and Taurolock® prescription recorded on IF database. CRBSI defined as positive central venous catheter blood cultures with fever±rigors. Simple cost analysis calculated at £8340 per hospital treatment for CRBSI (10 day in-patient admission) and Taurolock costing £11 per day.
Results All 16 patients (male 56.3%, mean age 44.8 years (range 23–73)) prescribed Taurolock® were selected. In the pre-treatment group mean duration from first CRBSI episode to Taurolock® prescription was 602±317 days. This pre-treatment group had a mean 9.8±6.5 CRBSI rate per 1000 catheter days. The treatment group (mean duration 557±269 days) had a mean 3.3±3.4 CVC related sepsis rate per 1000 catheter days. There was a significant difference (p<0.001) in CRBSI rate prior and subsequent to Taurolock® prescription. Treating CRSBI for 1 year in these 16 patients pre-Taurolock® cost approximately £367 000 (440 in-patient days and antibiotic costs). Approximate treatment group costs were £228 240 (£164 000 hospital costs for treating CRBSI and £64 240 for Taurolock treatment). One year cost savings of Taurolock® prescription was £138 760.
Conclusion Taurolock® significantly decreases CRBSI rate in HPN patients. These results are in keeping with a Canadian group that managed to decrease CRBSI following treatment in seven patients. (2) Taurolock® prescription generates considerable cost savings in this cohort of patients.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.